Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New smart insulin tool could simplify mealtime for teens with diabetes

NCT ID NCT07212179

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new self-learning bolus calculator that simplifies meal announcements for adolescents and young adults with type 1 diabetes using automated insulin delivery. Two participants used the system first in a hotel and then at home to see if it was safe and feasible. The goal was to help manage blood sugar levels more easily without needing complex meal calculations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

Mar 2026

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥14.0 and ≤21 years old at time of consent 2. HbA1c ≤ 10%. 3. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year 4. Having used an insulin pump within the last three months. 5. Currently using insulin for at least six months 6. Willingness to use insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections 7. Willingness to switch to a commercially approved insulin (e.g. lispro or aspart or biosimilar approved products) within the study pump as directed by the study team. 8. Has one or more supportive caregivers or companions living with the participant who are knowledgeable about emergency procedures for treatment of severe hypoglycemia and able to contact emergency services and study staff. 9. Acceptable forms of contraception for participants of child-bearing potential include hormonal treatments including IUD, abstinence from heterosexual intercourse, vasectomy in partner, barrier methods (e.g. condom or diaphragm). 10. For females, not currently known to be pregnant or breastfeeding. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued. 11. Willingness to use the study InsuLearn system (CGM, pump, and phone) during the study period. 12. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial. 13. Access to internet at home and ability to upload data during the study as needed. 14. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol. 15. Participant is proficient in reading and writing English. Exclusion Criteria: 1. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment 2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment 3. Pregnancy or intent to become pregnant during the trial 4. Currently breastfeeding or planning to breastfeed 5. Currently being treated for a seizure disorder 6. Planned surgery during study duration 7. History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted) 8. Treatment with any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals) 9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol. 10. Participation in another interventional trial at the time of enrollment. 11. Visual impairment/blindness that prevents proper interaction with study equipment 12. Participant who may have a falsely eligible HbA1c due to medical conditions or blood donations. 13. Participants in whom the G6 CGM may be inaccurate due to interference.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Virginia Center for Diabetes Technology

    Charlottesville, Virginia, 22903-2981, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.